Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 12:07, 20 December 2023

3,362 bytes added ,  12:07, 20 December 2023
no edit summary
Line 27: Line 27:  
|
 
|
 
|-
 
|-
−
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
+
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 34: Line 34:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || || || ||FQR|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 41: Line 41:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| ||
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 48: Line 48:  
|
 
|
 
|-
 
|-
−
|Chronic neutrophilic leukaemia||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
Line 55: Line 55:  
|
 
|
 
|-
 
|-
−
|Chronic eosinophilic leukaemia||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chelsea D. Kramish; Daynna J.Wolff
 
|Chelsea D. Kramish; Daynna J.Wolff
Line 62: Line 62:  
|
 
|
 
|-
 
|-
−
|Polycythaemia vera||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| || || || || ||FQR|| ||
 
|Polycythemia Vera (PV)
 
|Polycythemia Vera (PV)
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
Line 69: Line 69:  
|
 
|
 
|-
 
|-
−
|Essential thrombocythaemia||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| || || || || ||FQR|| ||
 
|Essential Thrombocythemia (ET)
 
|Essential Thrombocythemia (ET)
 
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
 
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Line 76: Line 76:  
|
 
|
 
|-
 
|-
−
|Primary myelofibrosis||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| || || || || ||FQR|| ||
 
|Primary Myelofibrosis (PMF)
 
|Primary Myelofibrosis (PMF)
 
|T. Niroshi Senaratne, UCLA
 
|T. Niroshi Senaratne, UCLA
Line 83: Line 83:  
|
 
|
 
|-
 
|-
−
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
+
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
 
|Juvenile Myelomonocytic Leukemia (JMML)
 
|Juvenile Myelomonocytic Leukemia (JMML)
 
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
 
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
Line 94: Line 94:  
|FQR has emailed SR several times, last 4/20/22
 
|FQR has emailed SR several times, last 4/20/22
 
|-
 
|-
−
|Myeloproliferative neoplasm, NOS||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
 
|Myeloproliferative Neoplasm (MPN), Unclassifiable
 
|Myeloproliferative Neoplasm (MPN), Unclassifiable
 
|Thomas Lee, MD, PhD, University of California, Los Angeles
 
|Thomas Lee, MD, PhD, University of California, Los Angeles
Line 101: Line 101:  
|
 
|
 
|-
 
|-
−
|Cutaneous mastocytosis||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| || || || || ||FQR|| ||
 
|Cutaneous Mastocytosis
 
|Cutaneous Mastocytosis
 
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
 
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
Line 108: Line 108:  
|
 
|
 
|-
 
|-
−
|Systemic mastocytosis||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| ||
 
|Systemic Mastocytosis
 
|Systemic Mastocytosis
 
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
 
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
Line 115: Line 115:  
|
 
|
 
|-
 
|-
−
|Mast cell sarcoma||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| || || || || ||FQR|| ||
 
|Mast Cell Sarcoma
 
|Mast Cell Sarcoma
 
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
 
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
Line 122: Line 122:  
|
 
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
 
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
 
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
 
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
Line 129: Line 129:  
|
 
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| || || || || ||FQR|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 143: Line 143:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts|Myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 150: Line 150:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm, hypoplastic|Myelodysplastic neoplasm, hypoplastic]]||Disease|| || || || || ||FQR|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 157: Line 157:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Myelodysplastic neoplasm with increased blasts||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic Syndrome (MDS) with Excess Blasts
 
|Myelodysplastic Syndrome (MDS) with Excess Blasts
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 164: Line 164:  
|
 
|
 
|-
 
|-
−
|Childhood myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
 
|Refractory Cytopenia of Childhood
 
|Refractory Cytopenia of Childhood
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 171: Line 171:  
|
 
|
 
|-
 
|-
−
|Childhood myelodysplastic neoplasm with increased blasts||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
 
|Refractory Cytopenia of Childhood
 
|Refractory Cytopenia of Childhood
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 178: Line 178:  
|
 
|
 
|-
 
|-
−
|Chronic myelomonocytic leukaemia||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| || || || || ||FQR|| ||
 
|Chronic Myelomonocytic Leukemia (CMML)
 
|Chronic Myelomonocytic Leukemia (CMML)
 
|Linsheng Zhang, MD, PhD
 
|Linsheng Zhang, MD, PhD
Line 185: Line 185:  
|
 
|
 
|-
 
|-
−
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| || || || || ||FQR|| ||
 
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
 
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
 
|Linsheng Zhang, MD, PhD
 
|Linsheng Zhang, MD, PhD
Line 192: Line 192:  
|
 
|
 
|-
 
|-
−
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
 
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
 
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
 
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
Line 199: Line 199:  
|
 
|
 
|-
 
|-
−
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
 
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
 
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
 
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
Line 206: Line 206:  
|
 
|
 
|-
 
|-
−
|Acute promyelocytic leukaemia with PML::RARA fusion
+
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
 
|Disease
 
|Disease
 
|
 
|
Line 222: Line 222:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion
+
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
 
|Disease
 
|Disease
 
|
 
|
Line 238: Line 238:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia with CBFB::MYH11 fusion
+
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
 
|Disease
 
|Disease
 
|
 
|
Line 254: Line 254:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia with DEK::NUP214 fusion
+
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
 
|Disease
 
|Disease
 
|
 
|
Line 270: Line 270:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia with RBM15::MRTFA fusion
+
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
 
|Disease
 
|Disease
 
|
 
|
Line 286: Line 286:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia with BCR::ABL1 fusion
+
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
 
|
 
|
Line 302: Line 302:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia with KMT2A rearrangement
+
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
 
|Disease
 
|Disease
 
|
 
|
Line 318: Line 318:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia with MECOM rearrangement
+
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
 
|Disease
 
|Disease
 
|
 
|
Line 350: Line 350:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Acute myeloid leukaemia with NPM1 mutation
+
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
 
|Disease
 
|Disease
 
|
 
|
Line 366: Line 366:  
|Add WHO reference
 
|Add WHO reference
 
|-
 
|-
−
|Acute myeloid leukaemia with CEBPA mutation
+
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
 
|Disease
 
|Disease
 
|
 
|
Line 382: Line 382:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia, myelodysplasia-related
+
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
 
|Disease
 
|Disease
 
|
 
|
Line 398: Line 398:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia with other defined genetic alterations
+
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
 
|Disease
 
|Disease
 
|
 
|
Line 414: Line 414:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Acute myeloid leukaemia with minimal differentiation
+
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
 
|Disease
 
|Disease
 
|
 
|
Line 430: Line 430:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia without maturation
+
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
 
|Disease
 
|Disease
 
|
 
|
Line 446: Line 446:  
|
 
|
 
|-
 
|-
−
|Acute myeloid leukaemia with maturation
+
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
 
|Disease
 
|Disease
 
|
 
|
Line 462: Line 462:  
|
 
|
 
|-
 
|-
−
|Acute basophilic leukaemia
+
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
 
|Disease
 
|Disease
 
|
 
|
Line 478: Line 478:  
|
 
|
 
|-
 
|-
−
|Acute myelomonocytic leukaemia
+
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
 
|Disease
 
|Disease
 
|
 
|
Line 494: Line 494:  
|
 
|
 
|-
 
|-
−
|Acute monocytic leukaemia
+
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
 
|Disease
 
|Disease
 
|
 
|
Line 510: Line 510:  
|
 
|
 
|-
 
|-
−
|Acute erythroid leukaemia
+
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
 
|Disease
 
|Disease
 
|
 
|
Line 526: Line 526:  
|
 
|
 
|-
 
|-
−
|Acute megakaryoblastic leukaemia
+
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
 
|Disease
 
|Disease
 
|
 
|
Line 542: Line 542:  
|
 
|
 
|-
 
|-
−
|Myeloid sarcoma
+
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 574: Line 574:  
|
 
|
 
|-
 
|-
−
|Myeloid neoplasm post cytotoxic therapy
+
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
 
|Disease
 
|Disease
 
|
 
|
Line 590: Line 590:  
|Check reference format
 
|Check reference format
 
|-
 
|-
−
|Myeloid neoplasms associated with germline predisposition
+
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
 
|Disease
 
|Disease
 
|ISSUE - FIX
 
|ISSUE - FIX
Line 606: Line 606:  
|
 
|
 
|-
 
|-
−
|Myeloid proliferations associated with Down syndrome
+
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
 
|Disease
 
|Disease
 
|
 
|
Line 622: Line 622:  
|
 
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement
+
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
 
|Disease
 
|Disease
 
|
 
|
Line 638: Line 638:  
|
 
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement
+
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
 
|Disease
 
|Disease
 
|
 
|
Line 654: Line 654:  
|
 
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement
+
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
 
|Disease
 
|Disease
 
|
 
|
Line 670: Line 670:  
|
 
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with JAK2 rearrangement
+
|[[HAEM5:Myeloid/lymphoid neoplasm with JAK2 rearrangement|Myeloid/lymphoid neoplasm with JAK2 rearrangement]]
 
|Disease
 
|Disease
 
|ISSUE- FIX
 
|ISSUE- FIX
Line 689: Line 689:  
|
 
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with FLT3 rearrangement
+
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
 
|Disease
 
|Disease
 
|ISSUE - FIX
 
|ISSUE - FIX
Line 705: Line 705:  
|
 
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion
+
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
 
|Disease
 
|Disease
 
|
 
|
Line 721: Line 721:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes
+
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
 
|Disease
 
|Disease
 
|
 
|
Line 737: Line 737:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion
+
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
 
|
 
|
Line 753: Line 753:  
|
 
|
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia with KMT2A rearrangement
+
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|Disease
 
|Disease
 
|
 
|
Line 769: Line 769:  
|
 
|
 
|-
 
|-
−
|Acute leukaemia of ambiguous lineage with other defined genetic alterations
+
|[[HAEM5:Acute leukaemia of ambiguous lineage with other defined genetic alterations|Acute leukaemia of ambiguous lineage with other defined genetic alterations]]
 
|Disease
 
|Disease
 
|
 
|
Line 785: Line 785:  
|
 
|
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia, B/myeloid
+
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
 
|Disease
 
|Disease
 
|
 
|
Line 801: Line 801:  
|
 
|
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia, T/myeloid
+
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
 
|Disease
 
|Disease
 
|
 
|
Line 817: Line 817:  
|
 
|
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia, rare types
+
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
 
|Disease
 
|Disease
 
|
 
|
Line 833: Line 833:  
|
 
|
 
|-
 
|-
−
|Acute leukaemia of ambiguous lineage, NOS
+
|[[HAEM5:Acute leukaemia of ambiguous lineage, NOS|Acute leukaemia of ambiguous lineage, NOS]]
 
|Disease
 
|Disease
 
|
 
|
Line 849: Line 849:  
|
 
|
 
|-
 
|-
−
|Acute undifferentiated leukaemia
+
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
 
|Disease
 
|Disease
 
|
 
|
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/13933"